Selected references

  1. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, et al. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J.Hepatol. 2011;54(3):591-592.
  2. Brinda BJ, Zhu HJ, and Markowitz JS. A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma. J.Chromatogr.B Analyt.Technol.Biomed.Life Sci. 8-1-2012;902:1-9.
  3. Fallahzadeh MK, Dormanesh B, Sagheb MM, et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am.J.Kidney Dis. 2012;60(6):896-903.
  4. Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 6-1-2010;70(8):848-855.
  5. Fried MW, Navarro VJ, Afdhal N, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 7-18-2012;308(3):274-282.
  6. Giorgi VS, Peracoli MT, Peracoli JC, et al. Silibinin modulates the NF-kappab pathway and pro-inflammatory cytokine production by mononuclear cells from preeclamptic women. J.Reprod.Immunol. 2012;95(1-2):67-72.
  7. Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic.Biol.Med. 5-1-2012;52(9):1658-1665.
  8. McBride A, Augustin KM, Nobbe J, et al. Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia. J.Oncol.Pharm.Pract. 2012;18(3):360-365.
  9. Molto J, Valle M, Miranda C, et al. Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients. Antimicrob.Agents Chemother. 2012;56(6):2837-2841.
  10. Oeckinghaus R, Cuneo A, Brockmeier J, et al. [Acute hepatic failure after ingestion of mushrooms]. Internist (Berl) 2012;53(5):619-624.
  11. Reddy KR, Belle SH, Fried MW, et al. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin.Trials 2012;9(1):102-112.
  12. Sarris J, Camfield D, and Berk M. Complementary medicine, self-help, and lifestyle interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: a systematic review. J.Affect.Disord. 2012;138(3):213-221.
  13. Suksomboon N, Poolsup N, Boonkaew S, et al. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J.Ethnopharmacol. 10-11-2011;137(3):1328-1333.
  14. Tiwari P, Kumar A, Balakrishnan S, et al. Silibinin-induced apoptosis in MCF7 and T47D human breast carcinoma cells involves caspase-8 activation and mitochondrial pathway. Cancer Invest 2011;29(1):12-20.
  15. Yakoot M and Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC.Gastroenterol. 2012;12:32.

This evidence-based monograph was prepared by The Natural Standard Research Collaboration

www.naturalstandard.com